Clinical Trials Browser

Interventional × BID protein, human × Other hematologic neoplasm × Clear all

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03906292 2025-03-10

CMLXI

Phase 2 Active not recruiting

125 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Phase 3 Terminated

44 enrolled 22 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01856283 2021-01-13

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Phase 2 Completed

87 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT04015024 2019-07-16

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Phase 2 Unknown

30 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

CMLXI

OPTIC-2L

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients